Copyright
©The Author(s) 2023.
World J Gastroenterol. Nov 7, 2023; 29(41): 5668-5682
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5668
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5668
Variable | Crohn’s disease(n = 92) | Ulcerative colitis(n = 127) | P value1 |
Age | 43.5 (29-53) | 41 (30-55) | 0.871 |
BMI | 23.8 (20.8-26.4) | 23.8 (21.4-25.9) | 0.787 |
Gender | 0.1572 | ||
Male | 44 (47.8%) | 73 (57.5%) | |
Female | 48 (52.5%) | 54 (42.5%) | |
Education | 0.192 | ||
Primary school | 32 (24.8%) | 27 (21.3%) | |
Secondary school | 52 (56.5%) | 78 (61.4%) | |
Degree | 8 (8.7%) | 22 (17.3%) | |
Job | 0.009 | ||
Unemployed | 56 (60.9%) | 51 (40.2%) | |
Employee | 16 (17.4%) | 38 (29.9%) | |
Entrepreneur | 8 (8.7%) | 16 (12.6%) | |
Worker | 4 (4.3%) | 7 (5.5%) | |
Student | 8 (8.7%) | 15 (11.8%) | |
Smoking status | 0.003 | ||
Active smoker | 16 (17.4%) | 20 (15.7%) | |
Past smoker | 32 (34.8%) | 16 (12.6%) | |
Non-smoker | 44 (47.8%) | 91 (71.7%) | |
Alcohol consumer | 0.8272 | ||
Yes | 8 (8.7%) | 10 (7.9%) | |
No | 84 (91.4%) | 117 (92.1%) | |
Comorbidity | 0.256 | ||
Diabetes | 8 (8.7%) | 4 (3.1%) | |
Hypertension | 20 (21.7%) | 10 (7.9%) | |
Recurrent UTI | 2 (2.2%) | 4 (3.1%) | |
Chronic renal failure | 1 (1.1%) | 2 (1.6%) | |
Nephrolithiasis | 3 (3.3%) | 1 (0.8%) | |
Asthma | 3 (3.3%) | - | |
COPD | 2 (2.2%) | 1 (0.8%) | |
Previous pneumonia | 1 (1.1%) | 1 (0.8%) | |
Dyslipidaemia | 12 (13%) | 35 (27.6%) | |
Arthritis | 32 (34.8%) | 34 (26.8%) | |
Hashimoto’s thyroiditis | 7 (7.6%) | 15 (11.8%) | |
Partner | 0.3222 | ||
Yes | 68 (73.9%) | 86 (67.7%) | |
No | 24 (26.1%) | 41 (32.3%) | |
Biologics (yes) | 76 (82.6%) | 78 (61.4%) | 0.0012 |
Steroids (yes) | 4 (4.3%) | 8 (6.3%) | 0.5312 |
Variable | Physically active(n = 125) | Physically inactive(n = 94) | P value1 |
IBD | 0.8922 | ||
Crohn’s disease | 53 (42.4%) | 39 (41.5%) | |
Ulcerative colitis | 72 (57.6%) | 55 (58.5%) | |
Age | 39 (29.5-52) | 44 (29-55.25) | 0.506 |
BMI | 24.25 (21.47-26.28) | 22.72 (20.95-25.71) | 0.185 |
Gender | 0.9522 | ||
Male | 67 (53.6%) | 50 (53.2%) | |
Female | 58 (46.4%) | 44 (46.8%) | |
Education | 0.903 | ||
Primary school | 34 (27.2%) | 25 (26.6%) | |
Secondary school | 75 (60%) | 55 (58.5%) | |
Degree | 16 (12.8%) | 14 (14.9%) | |
Job | 0.432 | ||
Unemployed | 59 (47.2%) | 48 (51.1%) | |
Employee | 30 (24%) | 24 (25.5%) | |
Entrepreneur | 15 (12%) | 9 (9.6%) | |
Worker | 6 (4.8%) | 5 (5.3%) | |
Student | 15 (12%) | 8 (8.5%) | |
Smoking status | 0.607 | ||
Active smoker | 21 (16.8%) | 15 (16%) | |
Past smoker | 29 (23.2%) | 19 (20.2%) | |
Non-smoker | 75 (60%) | 60 (63.8%) | |
Alcohol consumer | 0.8922 | ||
Yes | 10 (8%) | 4 (4.3%) | |
No | 115 (92%) | 90 (95.7%) | |
Comorbidity | 0.899 | ||
Diabetes | 8 (6.4%) | 4 (4.3%) | |
Hypertension | 20 (16%) | 10 (10.6%) | |
Recurrent UTI | 3 (3.2%) | 2 (2.1%) | |
Chronic renal failure | - | 1 (1.1%) | |
Nephrolithiasis | 3 (2.4%) | 2 (2.1%) | |
Asthma | 2 (1.6%) | 2 (2.1%) | |
COPD | 1 (0.8%) | 1 (1.1%) | |
Previous pneumonia | 2 (1.6%) | - | |
Dyslipidaemia | 28 (22.4%) | 19 (20.2%) | |
Arthritis | 32 (25.6%) | 34 (36.2%) | |
Hashimoto’s Thyroiditis | 12 (9.6%) | 10 (10.6%) | |
Partner | 0.5702 | ||
Yes No | 86 (68.8%) 39 (31.2%) | 68 (72.3%) 26 (27.7%) | |
Biologics(yes) | 91 (72.8%) | 63 (67%) | 0.3542 |
Steroids(yes) | 10 (8%) | 2 (2.1%) | 0.0592 |
PA variable | Crohn’s disease(n = 92) | Ulcerative colitis(n = 127) | P value1 |
Intense activities (Met min/wk) | 0 (0-192) | 0 (0-240) | 0.099 |
Moderate activities (Met min/wk) | 208 (0-536) | 140 (0-540) | 0.590 |
Mild activities (Met min/wk) | 293.75 (158.12-711.6) | 350 (120-840) | 0.940 |
Sitting time at work (min) | 210 (113-292.5) | 215 (125-292) | 0.719 |
Sitting time at home (min) | 174 (118.75-221.75) | 177 (115-229) | 0.855 |
Total score (Met min/wk) | 828.25 (339.37-1343.5) | 839 (390-1451) | 0.678 |
PA level | 0.995 | ||
Inactive | 39 (42.4%) | 55 (43.3%) | |
Sufficiently active | 50 (54.3%) | 66 (52%) | |
HEPA active | 3 (3.3%) | 6 (4.7%) |
PA variable | n (%) | PA active (Met min/wk) | PA inactive (Met min/wk) | P value1 |
PRO-2 CD | n = 92 | n = 53 | n = 39 | |
Remission | 27 (29.3%) | 1353 (1026.5-2064) | 210.75 (101.25-313.75) | 0.303 |
Mild | 24 (26.1%) | 1213.65 (1039.52-1534.75) | 346.25 (229.62-566.37) | |
Moderate | 41 (44.6%) | 1240.75 (879.67-1950) | 352.5 (45-468.75) | |
Overall | 92 (100%) | 1234 (981.75-1769.25) | 280 (157.5-465) | |
PRO-2 UC | n = 127 | n = 72 | n = 55 | |
Remission | 74 (58.3%) | 1345.35 (1057.5-1766.75) | 321.25 (204.25-535.87) | 0.994 |
Active | 53 (41.7%) | 1457 (952-1964.75) | 350 (0-574) | |
Overall | 127 (100%) | 1373.35 (990-1792.62) | 325 (111.5-538.5) |
Question (n = 219) | Completely agree | I think it is irrelevant | Partially agree | Partially disagree | Completely disagree | P value1 |
I think my IBD is a block to doing regular PA | 12 (5.5%) | 65 (29.7%) | 58 (26.5%) | 28 (12.8%) | 56 (25.6%) | 0.957 |
The treatment I am taking for my IBD is a block to performing regular PA | 5 (2.3%) | 78 (35.6%) | 15 (6.8%) | 16 (7.3%) | 105 (47.9%) | 0.520 |
I believe that engaging in regular PA may reactivate my IBD or, if already active, make it worse | 61 (27.9%) | 43 (19.6%) | 18 (8.2%) | 19 (8.7%) | 78 (35.6%) | < 0.001 |
I believe that performing regular PA may result in complications in my IBD (e.g., fistula formation, abscesses or other) | 13 (5.9%) | 45 (20.5%) | 21 (9.6%) | 26 (11.9%) | 114 (52.1%) | 0.527 |
I believe that performing regular PA can improve my IBD | 28 (12.8%) | 55 (25.1%) | 87 (39.7%) | 6 (2.7%) | 43 (19.6%) | 0.942 |
I believe that performing regular PA can protect me from new IBD recurrence | 25 (11.4%) | 74 (33.8%) | 87 (39.7%) | 18 (8.2%) | 15 (6.8%) | 0.538 |
My family doctor adequately informed me regarding the possibility of performing regular PA | 52 (23.7%) | 45 (20.5%) | 51 (23.3%) | 18 (8.2%) | 53 (24.2%) | 0.936 |
My gastroenterologist adequately informed me regarding the possibility of performing regular PA | 76 (34.7%) | 26 (11.9%) | 80 (36.5%) | 10 (4.6%) | 27 (12.3%) | 0.871 |
People close to me (e.g., relatives and friends) have repeatedly urged me to conduct a regular PA | 91 (41.6%) | 22 (10%) | 69 (31.5%) | 18 (8.2%) | 19 (8.7%) | 0.795 |
People close to me (relatives, friends) have repeatedly advised/banned me from conducting regular PA | 0 (%) | 35 (16%) | 29 (13.2%) | 24 (11%) | 131 (59.8%) | 0.291 |
Before receiving the diagnosis of IBD, I was more inclined to perform regular PA, but now, upon receiving the diagnosis, I feel less convinced to perform PA | 41 (18.7%) | 45 (20.5%) | 45 (20.5%) | 13 (5.9%) | 75 (34.2%) | < 0.001 |
Variable | Exp (B)/Odds ratio | 95%CI | P value |
Age (yr) | 0.996 | 0.976-1.018 | 0.743 |
Weight (Kg) | 1.017 | 0.992-1.041 | 0.180 |
Height (cm) | 1.018 | 0.989-1.048 | 0.231 |
BMI (Kg/m2) | 0.999 | 0.998-1.001 | 0.867 |
IBD (CD) | 0.931 | 0.503-1.721 | 0.819 |
IBD (UC) | 1.074 | 0.581-1.987 | |
Gender (Male) | 1.196 | 0.642-2.225 | 0.573 |
Gender (Female) | 0.836 | 0.449-1.556 | |
Partner (Yes) | 1.343 | 0.681-2.652 | 0.395 |
Partner (No) | 0.744 | 0.377-1.469 | |
Biologics (Yes) | 0.816 | 0.430-1.549 | 0.534 |
Biologics (No) | 1.225 | 0.646-2.325 | |
Arthritis (Yes) | 1.710 | 0.892-3.278 | 0.106 |
Arthritis (No) | 0.585 | 0.305-1.121 | |
Dyslipidaemia (Yes) | 0.747 | 0.343-1.627 | 0.463 |
Dyslipidaemia (No) | 1.338 | 0.615-2.913 | |
Diabetes (Yes) | 1.074 | 0.209-5.517 | 0.932 |
Diabetes (No) | 0.931 | 0.181-4.786 | |
Hypertension (Yes) | 0.622 | 0.204-1.893 | 0.403 |
Hypertension (No) | 1.608 | 0.528-4.893 | |
Hashimoto’s thyroiditis (Yes) | 1.121 | 0.462-2.717 | 0.800 |
Hashimoto’s thyroiditis (No) | 0.892 | 0.368-2.162 | |
Importance PA discussion (Likert 10-point scale) | 0.911 | 0.823-1.008 | 0.072 |
Employed | 0.857 | 0.501-1.464 | 0.571 |
Unemployed | 1.167 | 0.683-1.994 |
- Citation: Gravina AG, Pellegrino R, Durante T, Palladino G, D’Onofrio R, Mammone S, Arboretto G, Auletta S, Imperio G, Ventura A, Romeo M, Federico A. Inflammatory bowel diseases patients suffer from significant low levels and barriers to physical activity: The “BE-FIT-IBD” study. World J Gastroenterol 2023; 29(41): 5668-5682
- URL: https://www.wjgnet.com/1007-9327/full/v29/i41/5668.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i41.5668